

Treatment of advanced liver cell cancer with the drug thymostimulin

Submission date 19/12/2007	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 21/12/2007	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 30/12/2020	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Wolfgang Fleig

Contact details
Professor of Medicine
Medical Chairman and Chairman of the Board
University of Leipzig Hospitals and Clinics
Philipp-Rosenthal-Straße 27
Leipzig
Germany
04103

Additional identifiers

Study information

Scientific Title
Thymostimulin in advanced hepatocellular carcinoma: a phase II trial

Study objectives
To assess efficacy and safety of thymostimulin in the treatment of advanced hepatocellular carcinoma.

Please note that the phase III study of this trial is registered under <http://www.controlled-trials.com/ISRCTN64487365>.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethik-Kommission of the Medical Faculty of the Martin-Luther-University Halle-Wittenberg (Germany) in May 2000.

Primary study design

Interventional

Study design

Prospective uncontrolled single-centre phase II treatment study to assess efficacy and safety

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Locally advanced or metastasised hepatocellular carcinoma

Interventions

Thymostimulin 75 mg (Thymophysin CytoChemia® 25/50) subcutaneously for 5 days a week in addition to best supportive care as required.

Patients with tumour regress are allowed non-systemic concomitant treatment with Radiofrequency Thermal Ablation (RFTA) or Transarterial Chemoembolisation (TACE), if the tumour is accessible secondary to the study treatment. In case of tumour progress, patients are allowed to receive salvage therapy.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Thymostimulin

Primary outcome(s)

Overall survival as well as 1-, 2- and 3-year survival.

Key secondary outcome(s)

1. Tumour response and progression-free survival according to standard World Health Organization (WHO) criteria. Timepoints are:

1.1. Tumour response end of study (three years)

1.2. Overall progression-free survival

2. Toxicity according to Eastern Cooperative Oncology Group (ECOG) criteria

Completion date

31/03/2004

Eligibility

Key inclusion criteria

1. Biopsy- or image-proven locally advanced or metastatic hepatocellular carcinoma not amenable to or failing established treatment
2. Two-dimensional measurable lesion on imaging
3. Life expectancy greater than 3 months
4. Age 18 to 80 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

44

Key exclusion criteria

1. Pregnancy/lactation
2. Active second malignancy
3. Severe concomitant disease (e.g. New York Heart Association [NYHA] grade III - IV, serum creatinine level greater than 300 $\mu\text{mol/l}$)
4. Severe decompensated liver function (bilirubin greater than 5 mg/dl, International normalised ratio [INR] greater than or equal to 2.3)
5. Unable to give informed consent

Date of first enrolment

01/07/2000

Date of final enrolment

30/09/2002

Locations

Countries of recruitment

Germany

Study participating centre
University of Leipzig Hospitals and Clinics
Leipzig
Germany
04103

Sponsor information

Organisation
Martin-Luther-University Halle-Wittenberg (Germany)

ROR
<https://ror.org/05gqaka33>

Funder(s)

Funder type
University/education

Funder Name
Martin-Luther-University Halle-Wittenberg (Germany) - First Department of Medicine

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	13/03/2008	30/12/2020	Yes	No